ScreenerHero

HELPCybin Inc. Common Stock

NAS · US · Healthcare · Biotechnology · helus.com
12.59USD+0.96%Mkt Cap: 919.83M $P/E: —

Cybin Inc., doing business as Helus Pharma, a clinical stage pharmaceutical company, focuses on developing therapies to treat various psychiatric and neurological conditions.It develops HLP003, a deuterated psilocybin an…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap919.83M $
Enterprise Value1.58B $
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-148.00M $
Revenue/Share—
Last Price12.59 USD
Fiscal Year EndMar 2026
MR QuarterOct 2020
Employees100
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-6.82
PEG—
EV/EBITDA-11.06
EV/Revenue—
P/S—
P/B234.23
EPS (TTM)-4.06
EPS (Forward)-1.83
52W Range
12.0261% of range12.95
52W High12.95 USD
52W Low12.02 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-63.85%
ROA-58.92%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-133.27M $
CapEx (TTM)1.37M $
FCF Margin—
FCF Yield-8.98%
Net Debt-206.36K $
Net Debt/EBITDA0.00
Balance Sheet
Debt/Equity—
Current Ratio9.52
Quick Ratio8.38
Book Value/Sh0.0532 USD
Cash/Share0.0020 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:38
Split DateSep 19, 2024
Analyst Consensus
Rating1.0 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)41.67 USD
Upside (mean)+231.0%
Target Range15.39 USD – 70.58 USD
$15.39+231.0% to mean$70.58
# Analysts9
Ownership
Shares Out.73.06M
Float99.34M
Insiders2.74%
Institutions46.89%
Short Interest
Short Ratio2.0d
Short % Out.5.09%
Shares Short3.26M
Short (prev mo.)3.00M
Technical
SMA 507.425 (+69.6%)
SMA 2006.374 (+97.5%)
Beta0.56
S&P 52W Chg21.00%
Avg Vol (30d)1.99M
Avg Vol (10d)1.92M
Technical Indicators
RSI (14)74.0
MACD1.3567
MACD Signal1.2541
MACD Hist.+0.1026
BB Upper13.81 USD
BB Middle10.24 USD
BB Lower6.679 USD
BB Width69.59%
ATR (14)0.7121 USD
Vol Ratio (20d)1.23x